Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657420 | 0.97 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AKDM4EGRM4 | |
| SCHEMBL6654824 | 0.96 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AKDM4EGRM4 | |
| SCHEMBL6658940 | 0.95 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AKDM4EGRM4 | |
| SCHEMBL6663134 | 0.93 | PDE4D (0.41) | SMN1; SMN2NPC1RAB9AKDM4EPDE4A | |
| SCHEMBL6659309 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AKDM4EGRM4 | |
| SCHEMBL6656202 | 0.92 | NPC1 (0.46) | SMN1; SMN2NPC1RAB9AGRM4PDE4A | |
| SCHEMBL6844143 | 0.92 | AURKB (0.46) | SMN1; SMN2NPC1RAB9AKDM4EGRM4 | |
| SCHEMBL6656317 | 0.91 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AKDM4EGRM4 | |
| SCHEMBL6654732 | 0.91 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AKDM4EGRM4 | |
| SCHEMBL6654883 | 0.90 | PDE4D (0.41) | SMN1; SMN2NPC1RAB9AKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067252-A1 | Novel modified release formulation | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | claimed |
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | SMN1; SMN2 2642/4885NPC1 3307/4885RAB9A 2053/4885 |
| US-20040067252-A1 | Novel modified release formulation | ABCB11, SLC47A1, LIPA | SMN1; SMN2 2313/4885NPC1 69/4885RAB9A 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.